


*Supplementary Figure 1.* Age distribution in ABROAD cohort. The mean and median ages of the participants were 63.2 ± 13.3 and 65 years, respectively. The proportion of patients whose age was in the seventies was 31.0%, which was the highest percentage of any age group by decade.



*Supplementary Table 1. Concomitant cDMARDs in our cohort*

Concomitant use of cDMARDs		Elderly patients (≥ 65 years), N	Younger patients (< 65 years), N
MTX (+)	Other cDMARDs (-)	67	72
	Salazosulfapyridine	9	23
	Tacrolimus	4	4
	Bucillamine	4	8
	Mizoribine	3	2
	Gold	0	1
MTX (-)	Other cDMARDs (-)	17	8
	Salazosulfapyridine	24	8
	Tacrolimus	15	7
	Bucillamine	15	6
	Mizoribine	2	0
	Actarit	1	1
	Gold	0	1

cDMARDs: conventional disease-modifying anti-rheumatic drug; MTX: methotrexate

*Supplementary Figure 2.* Comparison of the low disease activity (LDA) achievement rate with abatacept treatment between the elderly and younger patient groups. The achievement rate of LDA at each point did not differ between the two age groups.

